Patheon will acquire IRIX Pharmaceuticals of Florence, S.C., which specializes in difficult to manufacture Active Pharmaceutical Ingredient (API) needs for drugs from early and late development through commercial launch. Patheon expects to close the transaction in the next 60 days.
Through the acquisition, Patheon secures additional API development and manufacturing services in the U.S., including high-potency (OEL< 30ng/m3) and controlled substances (Schedule 1-4), better meeting customers’ most challenging needs. IRIX manages the optimization of chemical processes and scale up for commercial API manufacturing at sites in Florence and Greenville, S.C.
Lukas Utiger, president, DPx Fine Chemicals and leader of the Patheon OneSource offering, said, “With this deal, we expand our Patheon OneSource integrated offering and leverage years of operational experience and scientific excellence at IRIX to complement Patheon’s existing API operations in Europe.”
The combined company offers process technologies including biocatalysis, homogeneous catalysis and microreactors, as well as a range of supply chain issues for customers.
“Combining companies with shared commitments to both scientific excellence and customer service drives industry excellence, and we are excited to become part of the Patheon network,” said Guy Steenrod, CEO of IRIX. “This is a strategic deal that allows us to help customers solve complex challenges with comprehensive, integrated solutions.”